AKYA Company Profile and Key Details

Q: Who are the executives of AKYA?

Dr. Frederic G. Pla Ph.D.Chief Operating OfficerPriyam ShahSenior Director of Bus. Devel. & Investor Relations StrategyMs. Jennifer KamocsayGen. CounselMr. Paul GrassSenior Vice President of SalesDr. Nikolay Samusik Ph.D.Co-FounderDr. Yury Goltsev Ph.D.Co-FounderMs. Marilee Moy M.B.A.Chief People OfficerDr. Niro Ramachandran Ph.D.Chief Bus. OfficerDr. Ehab A. El-Gabry M.D., Ph.D.Chief Medical OfficerMr. Joseph S. DriscollChief Financial OfficerMr. John Frederick EkChief Financial Officer, Principal Financial Officer & Principal Accounting OfficerMr. Clifford C. HoytVice President of Translational & Scientific AffairsMr. Brian McKelligonPres, Chief Executive Officer & DirectorDr. Garry P. Nolan Ph.D.Co-Founder, Independent Director & Head of the Scientific Advisory Board

NASDAQ : AKYA

Akoya Biosciences

$1.29

-0.07-5.15%

At Close 4:00 PM

Not Actively Trading

67.16

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Akoya Biosciences, Inc. (AKYA) stock declined over -5.15%, trading at $1.29 on NASDAQ, down from the previous close of $1.36. The stock opened at $1.29, fluctuating between $1.29 and $1.29 in the recent session.

Stock Snapshot

1.36

Prev. Close

64.44M

Market Cap

1.29

Day Low

-1.34375

P/E Ratio

-0.96

EPS (TTM)

-1.11

Cash Flow per Share

1.29

Open

49.95M

Number of Shares

1.29

Day High

25.2%

Free Float in %

1.1

Book Value

715.25K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 10, 2025	1.29	1.29	1.29	1.29	0
Jul 08, 2025	1.29	1.29	1.29	1.29	0
Jul 07, 2025	1.41	1.64	1.29	1.29	704.7K
Jul 03, 2025	1.35	1.40	1.35	1.36	309.67K
Jul 02, 2025	1.34	1.40	1.33	1.35	275.79K
Jul 01, 2025	1.30	1.38	1.30	1.32	530.39K
Jun 30, 2025	1.26	1.37	1.26	1.30	436.14K
Jun 27, 2025	1.32	1.37	1.24	1.24	3.6M
Jun 26, 2025	1.30	1.34	1.28	1.33	434.07K
Jun 25, 2025	1.25	1.30	1.21	1.28	68.9K
Jun 24, 2025	1.30	1.33	1.20	1.25	488.13K
Jun 23, 2025	1.26	1.30	1.22	1.29	184.52K
Jun 20, 2025	1.31	1.31	1.25	1.26	106.82K
Jun 18, 2025	1.25	1.35	1.21	1.30	304.87K
Jun 17, 2025	1.25	1.29	1.23	1.25	99.32K
Jun 16, 2025	1.23	1.30	1.23	1.27	200.37K
Jun 13, 2025	1.22	1.27	1.22	1.23	80.21K
Jun 12, 2025	1.31	1.34	1.25	1.26	103.79K
Jun 11, 2025	1.32	1.37	1.29	1.32	264.09K
Jun 10, 2025	1.17	1.33	1.15	1.33	558.21K

Contact Details

Marlborough, MA 01752

United States

https://www.akoyabio.com 855 896 8401

About Company

Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.

Stock Peers

ATRI

0.26+0.06%

Atrion Corporation$459.92 ICUI

1.85+1.11%

ICU Medical, Inc.$168.38 RGEN

2.37+1.68%

Repligen Corporation$143.60 LMAT

-1.38-1.33%

LeMaitre Vascular, Inc.$102.19 MMSI

2.51+3.10%

Merit Medical Systems, Inc.$83.35 HOLX

0.0000020.00%

Hologic, Inc.$76.01 COO

-0.41-0.56%

The Cooper Companies, Inc.$72.65 UTMD

-1.37-1.93%

Utah Medical Products, Inc.$69.57 PDEX

1.77+3.23%

Pro-Dex, Inc.$56.65 ATRC

-0.74-1.81%

AtriCure, Inc.$40.15

Company Overview

Akoya Biosciences, Inc. (NASDAQ:AKYA) closed at $1.29 USD, losing -$0.07 (-5.15%) from the previous close of $1.36. The stock is currently mid-range between its 52-week high and low $0.93 and $3.42. With a market capitalization of about $64.44 million, Akoya Biosciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.35). Key stats such as the average daily volume over the past year has been around 582.12 thousand shares, in line with its 52-week average. Headquartered in Marlborough, MA, Akoya Biosciences, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Brian McKelligon, the company employs approximately 205 people and listed since April 16, 2021. Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.14%, SMA50 6.04%, SMA200 -36.9%). The stock’s 14-day RSI is 51.9 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -62.28% below its high and over 38.56% above its low.

Valuation Metrics

Akoya Biosciences, Inc. trades at a P/E ratio of -1.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.79 and a price-to-book ratio of 8.39 trading at moderately above to book value. The P/FCF stands at -1.38, also above market averages.

Dividend & Fair Value

Akoya Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Akoya Biosciences, Inc. generated EPS of -$0.96 over the past year. Five-year average earnings growth is -23.03%. Wall Street analysts project EPS growth of 18.48% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.21. Next year's EPS is expected at $36.96. Akoya Biosciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 04, 2025, missed forecasts by 22.73%. The prior quarter beat by 10.34%. Over the last six quarters, Apple has recorded several small beats. These include 16.67% in May 13, 2024.

Shareholding & Insider Activity

Akoya Biosciences, Inc. has 49.95 million shares outstanding. The public float is 12.59 million shares, elevated short interest at 8.72% of float. This equals 2.64 million shares. The short ratio is 2.64 days. Institutional investors hold 254.29% of the float. Insiders own 72.58%. SCHNETTLER THOMAS P holds 2.74 million shares, Winkler Matthew has 984.51 thousand shares and Nolan Garry Ph.D. has 555.08 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Akoya Biosciences generated $96.63M in revenue, or $2.17 per share. Gross margin was 49.92%, operating margin -57.98%, and net profit margin -65.53%. Returns are negative, with ROA at -35.11% and ROE at -117.77%.
On valuation metrics, Akoya Biosciences trades at a P/E of -1.15, P/S of 0.79 and P/B of 8.39. The current ratio is 2.61 and quick ratio is 1.78. Operationally, the company’s inventory turnover is 1.39 and cash conversion cycle is 229.66 days. Debt-to-equity is 11.08, supported by a cash flow-to-debt ratio of -0.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Akoya Biosciences posted revenue of $96.63M, down slightly from $74.86M in the prior quarter. Gross profit was $48.24M (margin 49.92%). Operating income was - $56.03M (margin -58.0%). Net income was- $63.32M (EPS - $1.43).
The company ended the quarter with $83.13M in cash and short-term investments, a total debt of $85.71M, and net debt of $2.58M. Total assets were $180.37M, with equity of $53.77M. Financials further reflected weakness, with operating cash flow of - $50.90M, free cash flow of - $54.55M, and capital expenditures of - $3.65M.

Price Forecast & Outlook

Our AI price prediction model suggests that Akoya Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.53%, with price expected at $1.40 by July 24, 2025, within a range of $1.32 to $1.47 3-Month Outlook: Projected rise of 71.32%, reaching $2.21 by October 08, 2025, with a range of $1.83 to $2.41. 1-Year Outlook: Projected loss of -17.05%, with price at $1.07 by July 10, 2026, within a range of $0.00 to $0.10.

Key Takeaways

Akoya Biosciences, Inc. (NASDAQ:AKYA) shares are down -43.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Akoya Biosciences, Inc. trading at a premium to the broader market with a P/E of -1.15. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $11.85, suggesting 818.6% upside. Our AI forecast model points to short-term strength (8.53% over two weeks), a medium-term rise (71.32% over three months), and a longer-term loss (-17.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Akoya Biosciences, Inc. (AKYA) stock price?

Akoya Biosciences, Inc. (NASDAQ: AKYA) stock price is $1.29 in the last trading session. During the trading session, AKYA stock reached the peak price of $1.29 while $1.29 was the lowest point it dropped to. The percentage change in AKYA stock occurred in the recent session was -5.15% while the dollar amount for the price change in AKYA stock was - $0.07.

AKYA's industry and sector of operation?

The NASDAQ listed AKYA is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Akoya Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AKYA?

Dr. Frederic G. Pla Ph.D.
Chief Operating Officer
Priyam Shah
Senior Director of Bus. Devel. & Investor Relations Strategy
Ms. Jennifer Kamocsay
Gen. Counsel
Mr. Paul Grass
Senior Vice President of Sales
Dr. Nikolay Samusik Ph.D.
Co-Founder
Dr. Yury Goltsev Ph.D.
Co-Founder
Ms. Marilee Moy M.B.A.
Chief People Officer
Dr. Niro Ramachandran Ph.D.
Chief Bus. Officer
Dr. Ehab A. El-Gabry M.D., Ph.D.
Chief Medical Officer
Mr. Joseph S. Driscoll
Chief Financial Officer
Mr. John Frederick Ek
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Mr. Clifford C. Hoyt
Vice President of Translational & Scientific Affairs
Mr. Brian McKelligon
Pres, Chief Executive Officer & Director
Dr. Garry P. Nolan Ph.D.
Co-Founder, Independent Director & Head of the Scientific Advisory Board

How AKYA did perform over past 52-week?

AKYA's closing price is 38.56% higher than its 52-week low of $0.93 where as its distance from 52-week high of $3.42 is -62.28%.

How many employees does AKYA have?

Number of AKYA employees currently stands at 205.

Link for AKYA official website?

Official Website of AKYA is: https://www.akoyabio.com

How do I contact AKYA?

AKYA could be contacted at phone 855 896 8401 and can also be accessed through its website. AKYA operates from 100 Campus Drive, Marlborough, MA 01752, United States.

How many shares of AKYA are traded daily?

AKYA stock volume for the day was 715.25K shares. The average number of AKYA shares traded daily for last 3 months was 582.12K.

What is the market cap of AKYA currently?

The market value of AKYA currently stands at $64.44M with its latest stock price at $1.29 and 49.95M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	205
Beta	1.35
Sales or Revenue	$96.63M
5Y Sales Change%	0.911%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Instruments & Supplies

AKYA Company Profile and Key Details

Akoya Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways